All News

ACR20 Capitol

A Convergence of Ideas: COVID19 and ACR

d Kathryn H. Dao, M.D.

Since the beginning of the pandemic, rheumatologists scrambled to figure out how the SARS-CoV-2 virus will affect their patients with immune mediated inflammatory diseases (IMID). Meeting the needs of patients, managing a practice, and trying to balance a home life have many doctors stressed.

Read Article
Xeljanz4.jpg

Spondyloarthritis at ACR Convergence 2020

d Antoni Chan, MD, PhD

There are some really interesting poster and abstract presentations on spondyloarthritis at the ACR Convergence 2020. I’ll be covering these topics, and discussing select individual posters and abstracts during this meeting. 

Read Article
COVID.Flu_.Virus_.jpg (keep)

Infection and Rheumatic Diseases: A New Dawn

d Mrinalini Dey, MD

Infection in the setting of autoimmune rheumatic disease (ARD) has been the subject of increasing research and clinical interest for decades. Despite the huge burden of infection in patients with ARDs, this area of research has really been catapulted to the centre-stage of research agendas and coverage at congresses, including ACR 2020, with the arrival of the coronavirus disease 2019 (COVID-19) pandemic.

Read Article
ACR20 Podcast

QD Clinic Podcast - 106 thru 109

d Jack Cush, MD

Here is the last of our QD Clinics in Podcast form, just before we start ACR2020 coverage.



In this compilation from the past week we talk about



- HIV and arthritis



- Hyperuricemia in PsA



- An odd kind of dermatomyositis

Read Article
playbook2 ACR

Check Out the Virtual ACR Playbook

d Jack Cush, MD

If you need a plan for this weekend's ACR meeting, check out and download our latest, "Virtual ACR 2020 Playbook". The playbook covers: setting virtual learning goals, sessions you probably shouldn't miss, how to still have peer interactions, what to do if you only have time to "dabble' - and more.

Read Article
infx.pneumonia.jpg

TNF Inhibitor Associated Infectious Risk Greatest in First 6 Months

d Jack Cush, MD

The risk of serious infections (SIE) in RA patients given anti-TNF (TNFi) therapy is not static, instead it has been shown to be greatest in the first 6 months of use according to a recent report in Rheumatology. 

Read Article
RN.Laptop.jpg

ACR 2020 Your Way - Get Your Topic Emails

d Jack Cush, MD

ACR is but a few days away; the question is: how will you tackle this virtual meeting? RheumNow has created several options for learning the way you want to. First is to feed your need. Are you a lupologist? A gout maven? A Spondylitis sleuth? A drug safety wannabe?

Read Article
Dr. Dinesh Khanna (@sclerodermaUM): In post-hoc analysis of focuSSed trial of tocilizumab vs. placebo, disease duration, male gender, elevated acute phase reactants, and anti-SCL-70 Ab have a larger beneficial effect on FVC in early SSc-ILD. #ATS2020 #MiniSymposia @UMIntMed 10/

ATS Clinical Problems Assembly ATSCPAssembly ( View Tweet)

One of the many HOT sessions tomorrow #ACR20 I am planning on - IFN is center stage in autoinflammatory/autoimmune/infectious diseases especially-hope they cover IFN autoantibodies!! #COVID19 - @CCalabreseDO @JYazdanyMD @canallab @MaxKonigMD @AdamJBrownMD @TiphaineLft https://t.co/uDauMkGsjX
Leonard Calabrese LCalabreseDO ( View Tweet)
Association Between Changes in Pain Sensitization and Changes in Disease Activity After 12 Weeks of Disease Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis https://t.co/DLGFcDqrus #RA #pain Pain sensitization a management issue - disease control minor benefit

Links:

Peter Nash drpnash ( View Tweet)

Very psyched for this session tomorrow at #ACR20 on irAEs- this was a win for Twitter big time-thnxs for the shout out!!! looking for the next cut of data from the @rheum_covid alliance !!! @RheumNow @drdavidliew @CCalabreseDO @cappelliMD @HealioRheum https://t.co/qepFdLhmlV https://t.co/1jSek0sRqT

Links:

Leonard Calabrese LCalabreseDO ( View Tweet)
Happening now! Session 1T001 Opening Session of #ACR20. #ACRambassador Head on over, @ACRheum! https://t.co/eErNDB8pV6
Christina Downey, MD, RhMSUS cdowneymd ( View Tweet)
#ACR20 year in review @JYazdanyMD CIRT trial showing that MTX pneumonitis occurs but is very (very) rare. @RheumNow @jeffsparks @DanielHSolomon https://t.co/UbD4mhHBzq
Richard Conway RichardPAConway ( View Tweet)
Check out our "Virtual ACR2020 Playbook" to plan how you will take in and consume ACR20 from home and in your fuzzy slippers. https://t.co/5bsOFFXEMZ

Links:

Dr. John Cush RheumNow ( View Tweet)

#LTF Please wear your mask https://t.co/dzN0SDLb0T
Dr. John Cush RheumNow ( View Tweet)
Spanish cross-sectional study of 2,102 Rheumatic patients compared meds to COVID risk and showed Denosumab (0.58), zoledronate (0.62), calcium were negatively associated with COVID-19. Why? is it that they are less "sick"? https://t.co/BNbwsCz0rA

Links:

Dr. John Cush RheumNow ( View Tweet)

Eosinophilia in #RA is either due to a secondary problem (endemic parasitosis, drug hypersensitivity, etc) or may be associated with more severe RA - it is not associated with extraarticular manifestations of RA. https://t.co/J9rOA3cWC4

Links:

Dr. John Cush RheumNow ( View Tweet)

Presented at EADV Dermatology Congress - Mirikizumab, IL-23 inhibitor, shown superior to placebo & Secukinumab in Psoriasis. 465 patients given either PBO, MIR (2 doses) or SEC. Wk 52 MIR PASI90 PASI 90 (81%) vs SEC 69% https://t.co/EBCBUjkyWG

Links:

Dr. John Cush RheumNow ( View Tweet)

Racial/ethnic minorities with rheumatic Dz(RD) & COVID had increased odds of hospitalization & ventilatory support. 1,324 pts w/ RD+COVID, 36% hospitalized, 6% died. Compared to whites- Blacks Latinos & Asians had higher risk of hospital (OR=2.7, 1.7, 2.7) https://t.co/OGmarAfzLM

Links:

Dr. John Cush RheumNow ( View Tweet)

Cohort study (n 186) from NYC shows that patients with COVID and autoimmune disease were not at an increased risk for a ICU admission, intubation, or death (adjOR 0.79, 95%CI 0.37-1.67). AI pts had more comorbidities (26% vs. 13%), immunosuppressives https://t.co/TMCcKbns0f

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×